文献速递其他结缔组织病

在挪威系统性硬化症合并下消化道症状患者中进行的粪菌移植(ReSScue):一项2期随机双盲安慰剂对照试验

Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Rheumatol · 2025-01-31

这项在挪威四所大学医院开展的2期随机双盲安慰剂对照试验纳入67例系统性硬化症合并中重度下消化道症状(腹胀或腹泻)的成人患者,按1:1随机分配至安慰剂组(n=34)或标准化厌氧培养人肠道微生物组(ACHIM)粪菌移植组(n=33),在第0周和第2周进行肠道输注。主要终点为第0周至第12周最严重下消化道症状评分变化,ACHIM组为-0.13(95%CI -0.37至0.11),安慰剂组为-0.33(95%CI -0.57至-0.09),平均边际效应0.20(95%CI -0.12至0.52;p=0.22),组间无显著差异。ACHIM耐受性良好,但未改善下消化道症状。

要点

  • ACHIM粪菌移植组第12周最严重下消化道症状评分变化-0.13,安慰剂组-0.33,组间无显著差异(p=0.22)。
  • ACHIM组16例(48%)报告不良事件,安慰剂组19例(56%),多为轻度短暂胃肠道症状。
  • 胃镜检查中一名参与者发生十二指肠穿孔。

核心结论

  • ACHIM粪菌移植在系统性硬化症患者中耐受性良好,但未改善下消化道症状。

研究设计与样本

  • 2期随机双盲安慰剂对照试验,在挪威四所大学医院开展,纳入18-85岁系统性硬化症合并中重度下消化道症状(腹胀或腹泻)的成人患者。
  • 参与者按1:1随机分配至安慰剂组(n=34)或ACHIM组(n=33),在第0周和第2周接受肠道输注,按最严重症状(腹胀或腹泻)分层。
  • 主要终点为第0周至第12周最严重下消化道症状变化,采用UCLA SCTC GIT 2.0评分系统在意向治疗人群中评估。
  • 安全性在所有接受至少一次输注的参与者中于第0、2、4、6、12周评估。
  • 试验在ClinicalTrials.gov注册,注册号NCT04300426。

主要发现

  • 2020年9月24日至2022年1月14日共纳入67例参与者,安慰剂组34例,ACHIM组33例;平均年龄58.91岁(SD 11.59);女性62例(93%),男性5例(7%);抗着丝点抗体阳性50例(75%)。
  • 第0周至第12周最严重下消化道症状变化:ACHIM组-0.13(95%CI -0.37至0.11),安慰剂组-0.33(95%CI -0.57至-0.09),平均边际效应0.20(95%CI -0.12至0.52;p=0.22)。
  • 不良事件:ACHIM组16例(48%)报告,安慰剂组19例(56%)报告,多为轻度短暂胃肠道症状。
  • 胃镜检查期间一名参与者发生十二指肠穿孔。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrointestinal tract involvement is highly prevalent in systemic sclerosis, with few treatment options. We assessed the efficacy and safety of faecal microbiota transplantation using standardised anaerobic cultivated human intestinal microbiome (ACHIM) as a novel treatment option for patients with systemic sclerosis and symptomatic lower gastrointestinal tract involvement. METHODS: In this phase 2, randomised, double-blind, placebo-controlled trial done at four university hospitals in Norway, we enrolled adults aged 18-85 years with systemic sclerosis and moderate-to-severe lower gastrointestinal tract symptoms (bloating or diarrhoea). Participants were randomly assigned 1:1 to intestinal infusions of placebo or ACHIM at weeks 0 and 2, stratified by worst symptom (bloating or diarrhoea). The primary endpoint was change in worst lower gastrointestinal tract symptom (bloating or diarrhoea) from week 0 to week 12, measured using the University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 scoring system in the intention-to-treat population. Safety was assessed at weeks 0, 2, 4, 6, and 12 in all participants who received at least one infusion. A person with lived experience of systemic sclerosis was involved in the study planning and conduct. This trial was registered at ClinicalTrials.gov, NCT04300426. FINDINGS: Between Sept 24, 2020, and Jan 14, 2022, 67 participants were enrolled and randomly allocated to placebo (n=34) or ACHIM (n=33). Mean age was 58·91 years (SD 11·59). 62 (93%) of 67 participants were women, five (7%) were men, and 50 (75%) were anti-centromere antibody positive. Change in worst lower gastrointestinal tract symptom from week 0 to week 12 did not differ between participants who received ACHIM (-0·13, 95% CI -0·37 to 0·11) and participants who received placebo (-0·33, -0·57 to -0·09; average marginal effect 0·20, 95% CI -0·12 to 0·52; p=0·22). Adverse events, mostly mild and short-lived gastrointestinal tract symptoms, were reported by 16 (48%) of 33 participants in the ACHIM group and 19 (56%) of 34 in the placebo group. During gastroscopy, one participant had a duodenal perforation. INTERPRETATION: Faecal microbiota transplantation with ACHIM was well tolerated in participants with systemic sclerosis but did not result in an improvement in lower gastrointestinal tract symptoms. FUNDING: KLINBEFORSK. TRANSLATION: For the Norwegian translation of the abstract see Supplementary Materials section.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fretheim H, Barua I, Bakland G, et al. Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2025. PMID: 39900089. doi:10.1016/S2665-9913(24)00334-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。